Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short vs Long Adjuvant Imatinib in High-Risk GIST
NCT00116935Phase 3Completed
- Sponsor
- Scandinavian Sarcoma Group
- Start
- Feb 2004
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imatinib in gastrointestinal stromal tumor (GIST) (2 arms), sponsored by Scandinavian Sarcoma Group. Primary endpoint: Recurrence-free survival at 5 years. Started Feb 2004; status: completed.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT00116935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00116935.